Mitochondrial Targeting of Metformin Enhances Its Activity against Pancreatic Cancer
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F60461373%3A22330%2F16%3A43902059" target="_blank" >RIV/60461373:22330/16:43902059 - isvavai.cz</a>
Alternative codes found
RIV/86652036:_____/16:00469007 RIV/67985823:_____/16:00469007 RIV/00179906:_____/16:10331057
Result on the web
<a href="http://dx.doi.org/10.1158/1535-7163.MCT-15-1021" target="_blank" >http://dx.doi.org/10.1158/1535-7163.MCT-15-1021</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1158/1535-7163.MCT-15-1021" target="_blank" >10.1158/1535-7163.MCT-15-1021</a>
Alternative languages
Result language
angličtina
Original language name
Mitochondrial Targeting of Metformin Enhances Its Activity against Pancreatic Cancer
Original language description
Pancreatic cancer isone of the hardest-to-treat types of neoplastic diseases. Metformin, a widely prescribed drug against type 2 diabetes mellitus, is being trialed as an agent against pancreatic cancer, although its efficacy is low. With the idea of delivering metformin to its molecular target, the mitochondrial complex I (CI), we tagged the agent with the mitochondrial vector, triphenylphosphonium group. Mitochondrially targeted metformin (MitoMet) was found to kill a panel of pancreatic cancer cells three to four orders of magnitude more efficiently than found for the parental compound. Respiration assessment documented CI as the molecular target for MitoMet, which was corroborated by molecular modeling. MitoMet also efficiently suppressed pancreatic tumors in three mouse models. We propose that the novel mitochondrially targeted agent is clinically highly intriguing, and it has a potential to greatly improve the bleak prospects of patients with pancreatic cancer.
Czech name
—
Czech description
—
Classification
Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
FD - Oncology and haematology
OECD FORD branch
—
Result continuities
Project
Result was created during the realization of more than one project. More information in the Projects tab.
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2016
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Molecular Cancer Therapeutics
ISSN
1535-7163
e-ISSN
—
Volume of the periodical
15
Issue of the periodical within the volume
12
Country of publishing house
US - UNITED STATES
Number of pages
12
Pages from-to
2875-2886
UT code for WoS article
000390092800006
EID of the result in the Scopus database
2-s2.0-85008312167